Durata Therapeutics

Durata Therapeutics was a clinical-stage pharmaceutical company founded in 2009 around anti-infective assets acquired from Pfizer's Vicuron division, headquartered first in Morristown, New Jersey and from 2012 in Chicago, Illinois. Its lead candidate was dalbavancin, a long-acting semisynthetic lipoglycopeptide antibiotic taken into Phase III trials from 2011 for acute bacterial skin and skin-structure infections and later marketed as Dalvance. The company was backed by Canaan Partners and was acquired by Actavis (now Allergan) on November 17, 2014 for approximately $675 million, at which point it ceased to operate as an independent entity. Durata Therapeutics published no developer program, no public API, and no machine-readable API artifacts; its corporate domain duratatherapeutics.com no longer resolves. This profile is retained as a historical company record in the API Evangelist network.

Durata Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Pharmaceuticals, Biotechnology, Life Sciences, and Health.

🌐 Visit website 📡 Source on GitHub
2.2/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-20 · rubric v0.12.0
0 APIs
CompanyPharmaceuticalsBiotechnologyLife SciencesHealthAnti-InfectivesDrug DevelopmentAcquiredDefunct

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-08-20 · rubric v0.12.0
Composite quality — 2.2/100 · minimal
Contract Quality 0.0 / 21
Developer Ergonomics 0.0 / 17
Access Clarity 0.0 / 17
Operational Transparency 0.0 / 11
Contract Governance 0.0 / 10
Discoverability 4.3 / 9
Regulatory Posture 0.0 / 15
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 10
Documented Reversibility 0 / 6
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
A2A Agent Card 0 / 8
Dry-Run / Simulate Mode 0 / 4
Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.
The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/durata-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Source (apis.yml)

apis.yml Raw ↑ 
aid: durata-therapeutics
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/durata-therapeutics.png
name: Durata Therapeutics
description: Durata Therapeutics was a clinical-stage pharmaceutical company founded in 2009 around anti-infective assets
  acquired from Pfizer's Vicuron division, headquartered first in Morristown, New Jersey and from 2012 in Chicago, Illinois.
  Its lead candidate was dalbavancin, a long-acting semisynthetic lipoglycopeptide antibiotic taken into Phase III trials
  from 2011 for acute bacterial skin and skin-structure infections and later marketed as Dalvance. The company was backed
  by Canaan Partners and was acquired by Actavis (now Allergan) on November 17, 2014 for approximately $675 million, at which
  point it ceased to operate as an independent entity. Durata Therapeutics published no developer program, no public API,
  and no machine-readable API artifacts; its corporate domain duratatherapeutics.com no longer resolves. This profile is retained
  as a historical company record in the API Evangelist network.
url: https://raw.githubusercontent.com/api-evangelist/durata-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- canaan-partners
x-tier: stub
x-tier-reason: defunct-no-api-surface
x-status: acquired
x-acquired-by: Actavis (now Allergan)
x-acquired-date: '2014-11-17'
x-defunct: true
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-20'
tags:
- Company
- Pharmaceuticals
- Biotechnology
- Life Sciences
- Health
- Anti-Infectives
- Drug Development
- Acquired
- Defunct
apis: []
common: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-20'
  status: nochange
  artifacts_added: 0
  pass: local-v1
  notes: Company defunct since the 2014 Actavis acquisition; duratatherapeutics.com does not resolve (no NS/SOA). Domain-security,
    security-program, authentication and OAuth-scope probes all returned empty. No API, developer portal, SDK, or specification
    surface exists to harvest.